Revive Confirms No Material Undisclosed Information
12 Août 2021 - 3:56PM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2021/8/12/zsiawScreen_Shot_2021-08-12_at_9.50.40_AM.png)
Revive
Confirms No Material Undisclosed Information
Toronto, Ontario, Canada -- August 12, 2021 -- InvestorsHub
NewsWire -- Revive Therapeutics Ltd. ("Revive" or the
"Company") (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences
company focused on the research and development of therapeutics for
medical needs and rare disorders, announces that its management is
not aware of any undisclosed material information relating to the
Company that may be contributing to the recent increase in its
trading activity.
About Revive Therapeutics
Ltd.
Revive is a life sciences company focused on the research and
development of therapeutics for infectious diseases and rare
disorders, and it is prioritizing drug development efforts to take
advantage of several regulatory incentives awarded by the FDA such
as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric
Disease designations. Currently, the Company is exploring the use
of Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. Through its
subsidiary Psilocin Pharma Corp., Revive is advancing the
development of Psilocybin-based therapeutics in various diseases
and disorders. Revive's cannabinoid pharmaceutical portfolio
focuses on rare inflammatory diseases and the company was granted
FDA orphan drug status designation for the use of Cannabidiol (CBD)
to treat autoimmune hepatitis (liver disease) and to treat ischemia
and reperfusion injury from organ transplantation. For more
information, visit www.ReviveThera.com.
For more information please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel:1 888 901 0036
Email:mfrank@revivethera.com
Website:www.revivethera.com
Neither the Canadian Securities
Exchange nor its Regulation Services Provider have reviewed or
accept responsibility for the adequacy or accuracy of this
release.
Revive Therapeutics (CSE:RVV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Revive Therapeutics (CSE:RVV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Revive Therapeutics Ltd (Canadian Securities Exchange): 0 recent articles
Plus d'articles sur Revive Therapeutics Ltd